Vivatides Therapeutics Raises $54M for RNA Expansion
Vivatides Therapeutics announced a $54 million Series A round, led by Qiming Venture Partners and backed by several other investors. The funding will accelerate its proprietary extrahepatic delivery platform, designed to transport RNA molecules such as siRNA and antisense oligonucleotides beyond the liver. By overcoming the long‑standing tissue‑targeting barrier, Vivatides aims to broaden RNA‑based therapies into cancer, cardiovascular and other chronic diseases. The oversubscribed raise signals strong investor confidence in the company’s scientific approach and market potential.
Loyal Raises $100 Million: Dog Longevity Drugs Targeting IGF-1 and PPAR Pathways
Loyal, a veterinary biotech firm, announced a $100 million financing round to advance its canine longevity platform. The company targets the IGF‑1 and PPAR pathways to develop drugs that extend the lifespan of senior and large‑breed dogs. It has secured conditional...
Minimally-Invasive Stenting Effectively Treats Painful Post-Thrombotic Syndrome
Washington University researchers led the NIH‑funded C‑TRACT trial, showing that minimally invasive venous stenting markedly improves outcomes for patients with post‑thrombotic syndrome. Among 225 participants with severe disease, stent plus standard therapy reduced the persistence of severe syndrome to 40%...
Evidence for Retrotransposon Suppression to Reduce Biological Age in Humans
Researchers evaluated two FDA‑approved nucleoside reverse transcriptase inhibitor (NRTI) regimens in healthy adults to see if they could blunt age‑related epigenetic drift. Over 12 weeks, the emtricitabine/tenofovir‑alafenamide (FTC/TAF) combo lowered multiple DNA‑methylation clocks, including DunedinPACE and PhenoAge, and reduced inflammatory...
TANGENT Phase 3 Study Meets Primary and Secondary Endpoints, SynOx Reports
SynOx Therapeutics reported that its Phase 3 TANGENT study of emactuzumab met both primary and secondary endpoints in tenosynovial giant cell tumor (TGCT). The five‑dose, eight‑week regimen achieved statistically significant RECIST responses and tumor volume reductions at six months. Patients also...
Powering a Smarter, Scalable Future for Bioprocessing
Yokogawa introduced Bio Pilot, a vendor‑agnostic platform that integrates equipment, data and workflows across both upstream and downstream bioprocessing. The solution replaces fragmented, manual operations with real‑time analytics, model‑predictive control and a no‑code workflow editor that automates SOPs. Early deployments...
F.D.A. Calls on Drug Developers to Publish Missing Data From Thousands of Trials
The FDA announced it has dispatched more than 2,200 letters to drug makers, device manufacturers and researchers, demanding the publication of clinical‑trial results that remain absent from ClinicalTrials.gov. An internal analysis shows roughly 30 % of studies under FDA review have...
ROIS Expands US Injectable Manufacturing Capacity
ROIS has completed the acquisition of a 370,000‑square‑foot injectable manufacturing facility in Phoenix, Arizona, adding high‑potent fill/finish and lyophilization capabilities for biologics and antibody‑drug conjugates (ADCs). The site already holds FDA, EMA and Japanese regulatory approvals, enabling immediate support for...
FDA Narrows in on Search for New Biologics and Vaccines Leader
The U.S. Food and Drug Administration is close to naming a new director for its Center for Biologics Evaluation and Research (CBER), ending the turbulent tenure of Vinay Prasad. Sources say the leading candidate is Dr. Susan K. Lee, a...
October - December 2022 | Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System...
The FDA’s Adverse Event Reporting System (FAERS) prompted a wave of labeling revisions between 2023 and 2025, adding new safety warnings to dozens of drugs. Notable changes include hypersensitivity alerts for cabotegravir injectables, fecal incontinence risks for several atypical antipsychotics,...
Pharmaceutical Executive Daily: FDA Issues Second CRL for Replimune's RP1 Melanoma Treatment
The FDA issued a second complete response letter rejecting Replimune’s biologics license application for RP1 combined with nivolumab in advanced melanoma, citing insufficient data to isolate RP1’s contribution. Replimune’s CEO warned of job cuts and a scale‑back of U.S. manufacturing....
Spinal Elements Wins FDA Clearance for Ventana A ALIF System, Expands 3D-Printed Spine Portfolio
Spinal Elements has secured FDA 510(k) clearance for its Ventana A anterior lumbar interbody fusion (ALIF) system, the latest addition to its 3D‑printed titanium spine portfolio. The company reports that the first U.S. cases have already been completed, demonstrating early...
Kailera Therapeutics (KLRA) IPO Deck
Kailera Therapeutics (KLRA) is preparing an initial public offering to fund its GLP‑1‑based obesity drug platform, which includes both injectable and oral candidates. The company’s pipeline spans multiple clinical stages, from early‑phase studies to late‑stage trials, positioning it to capture...
A Novel Approach To The Treatment Of Antibiotic Resistant Infections
Researchers have engineered microscopic, cell‑like particles that hunt drug‑resistant bacteria while sparing healthy microbes. The particles use protein‑based recognition to bind unique bacterial markers and deliver toxic proteins or bactericidal chemicals in a two‑step process. Laboratory tests showed a single...
NHS Improves Genetic Testing for Minority Ethnic Cancer Patients
The NHS has expanded its pre‑chemotherapy genetic screening to include a fifth DPYD gene variant that is more common among Black and minority‑ethnic patients. Previously, tests only covered four variants prevalent in white European populations, leaving many patients at risk...
UniQure Investors Face April 13 Deadline to Lead Securities‑fraud Lawsuit
UniQure N.V. shareholders who purchased ordinary shares between September 24 and October 31, 2025, have until April 13, 2026 to file a motion to serve as lead plaintiff in a securities‑fraud class action. The lawsuit, filed by Rosen Law Firm,...
Sibel Health Wins FDA Clearance for Maternal-Fetal Monitoring Platform
Sibel Health announced FDA 510(k) clearance for ANNE Maternal, a wireless wearable that continuously monitors a pregnant woman's vital signs, fetal heart rate, and uterine activity. The platform adds visual and audio alarms plus an automated Modified Early Obstetric Warning...
Sarcopenia -- New Clues
Recent preclinical and clinical work links low‑grade inflammation to age‑related muscle loss, or sarcopenia, and shows that ibuprofen can blunt this process. In 20‑month‑old rats, a five‑month ibuprofen regimen cut inflammatory markers by up to 60% and boosted post‑prandial muscle...
Fragments vs the E3 Ligase KLHL12
Researchers at Vanderbilt screened 13,824 fragments against the E3 ligase KLHL12, a protein overexpressed in many cancers but absent from heart tissue. The campaign yielded 35 initial hits, with compound 7k emerging as the most potent, displaying sub‑micromolar affinity in...
Person Functionally Cured of HIV After Bone Marrow Transplant From Sibling
A 63‑year‑old man achieved functional cure of HIV after receiving a bone‑marrow transplant from his brother, who carries two copies of the CCR5 Δ32 mutation that blocks the virus’s primary entry point. The donor cells fully engrafted in the recipient’s blood,...
COSMOS Pharmaceutical Posts Nine‑month Profit Rise to ¥22.7 Bn, Revenue up 7.7%
COSMOS Pharmaceutical Corp (3349.T) posted a nine‑month net profit of ¥22.748 bn, up from ¥22.343 bn a year earlier, while revenue rose 7.7% to ¥810.380 bn. The results highlight continued top‑line momentum for the Tokyo‑listed biotech firm.
Appointments and Advancements for April 13, 2026
On April 13, 2026 three biotech firms filed patents on novel drug candidates. Accure Therapeutics disclosed oligopeptide derivatives that inhibit matrix metalloproteinases MMP‑2 and MMP‑9, enzymes linked to cancer invasion and fibrosis. Merck Sharp & Dohme (MSD) introduced indazole‑based blockers of HCN1/2...
Allogene’s First Cut of Data on ‘Off-the-Shelf’ CAR-T Shows Promise
Allogene Therapeutics reported that its off‑the‑shelf CAR‑T candidate cleared all detectable lymphoma cells in just over half of trial participants. The interim analysis stems from the pivotal ALLO‑501/ALLO‑501A study in relapsed or refractory B‑cell lymphoma. Researchers highlighted a complete molecular...
GSK Reports Strong Results for B7-H4 ADC in Gynecological Cancers
GSK’s investigational antibody‑drug conjugate mocertatug rezetecan (Mo‑Rez) demonstrated robust activity in its Phase 1 BEHOLD‑1 trial, achieving a 62% objective response rate in platinum‑resistant ovarian cancer and 67% in recurrent or advanced endometrial cancer. The drug targets the B7‑H4 immune checkpoint,...
Orforglipron
Orforglitron, an oral non‑peptide GLP‑1 receptor partial agonist developed by Eli Lilly and Chugai, received FDA approval for chronic weight management. The drug distinguishes itself from oral semaglutide by requiring no fasting or special dosing constraints, enabling once‑daily administration. Clinical trials...
Researchers Use Nanomaterials and Ultrasound to Create Light Inside the Body
Stanford researchers have created a noninvasive method that uses focused ultrasound to activate biocompatible ceramic nanoparticles, generating light at any point inside the body. The proof‑of‑concept, demonstrated in mice, produced blue 490 nm light that could stimulate neurons and mimic photodynamic...
USP Adds Tamiflu, Trulicity to Vulnerable List as Upstream Analysis Reshapes Supply Concerns
The United States Pharmacopeia (USP) has refreshed its vulnerable medicines list, adding Tamiflu (oseltamivir) and Trulicity (dulaglutide) after expanding its risk assessment to include key starting materials (KSMs). The new analysis shows 48 of the 100 flagged drugs depend on...
Allogene Stock Sails After CAR T Clears Residual Lymphoma in Early Data Cut
Allogene Therapeutics reported interim results from its Phase 2 ALPHA3 trial showing its off‑the‑shelf CAR‑T product cema‑cel cleared measurable residual disease in 58.3% of patients versus 16.7% in the observation arm. The therapy also achieved a 97.7% drop in circulating tumor...
How This Biotech Stock Skirted Today's Selloff
Revolution Medicines (RVMD) surged 35.5% to $131.35, briefly touching a record $135.81 after reporting that its pancreatic‑cancer pill daraxonrasib cut death risk by 60% in a Phase 3 trial. Leerink and Guggenheim raised price targets to $147 and $174, respectively. The...
Hidden Antivirals Discovered in a Plant-Derived Supplement
Researchers identified a new family of trace molecules, dubbed dicitriosides, hidden in a 90 %‑purity isoquercitrin supplement. These triterpenoid‑cinnamate compounds exhibit nanomolar potency against Ebola, Zika and SARS‑CoV‑2, outperforming the original mixture by roughly 25‑fold. The antiviral activity was isolated to...
BioNTech's HER2 ADC Succeeds in Phase 2 Study, FDA Filing Planned
BioNTech announced that its HER2‑targeted antibody‑drug conjugate, trastuzumab pamirtecan (formerly BNT323), achieved robust efficacy in a Phase 2 trial of HER2‑positive metastatic breast cancer. The study reported a 45% overall response rate and a median progression‑free survival of 8.2 months, with...
Revolution Rises 40% as Pancreatic Cancer Drug Doubles Survival
Revolution Medicines announced that its oral RAS inhibitor daraxonrasib doubled overall survival in patients with previously treated metastatic pancreatic ductal adenocarcinoma, achieving 13.2 months versus 6.7 months on chemotherapy. The Phase 3 RASolute 302 interim analysis was declared final, prompting the company...
Rigorous Trials, Not Hype, Prove Cancer Drug Value
Today's $RVMD study outcome in pancreatic cancer is a good lesson for all the $IBRX @DrPatrick fans. Stop with all the hand-waving "cancer cure" podcasting social media nonsense. Shut up and run well-designed clinical trials with definitive endpoints. If you have...
Nanodiscs Reveal Antibody Interactions for HIV, Ebola Vaccines
Nanodisc technology enables viral surface proteins from HIV and Ebola to be studied within lifelike membrane environments, offering new insights into antibody interactions and accelerating the development of next-generation vaccines. vaccinedesign
The IPO Buzz: Obesity-Focused Kailera Therapeutics Sets $500 Million IPO
Kailera Therapeutics, an obesity‑focused biotech developing a weekly GLP‑1 injection and a daily oral pill, filed an S‑1/A to raise $500 million. The company will offer 33.33 million shares at $14‑$16 each, which would place its market value near $1.8 billion if priced...
CRISPR Turns 25: Explore Its Past, Present, Future
Introducing the GEN Keynote Webinar: "CRISPR at 25: The Past, Present, and Future of Genome Editing" Guest speaker: Rodolphe Barrangou @CRISPRchef May 4, 2026: noon ET/9 am PT Sponsored by @elevatebio https://t.co/cYsSsaod4Y via @GENbio
Busy Biotech Day Highlights Promising Advances and Insightful Commentary
As usual, excellent summary by @ldtimmerman @timmermanreport of busy and promising biotech news day - as always delivered w insight and heart (especially thoughtful comments re: revmed drug in context of poignant recent @BenSasse interview)
Leukogene Therapeutics Announces Two Presentations at the AACR Annual Meeting 2026 Highlighting MHC Class II-Engager Immunotherapies
Leukogene Therapeutics announced two poster presentations at the 2026 AACR Annual Meeting in San Diego, showcasing its MHC class II‑engager immunotherapy candidates for acute myeloid leukemia and pancreatic cancer. The posters will be displayed during the Immunology session on bi- and...
FDA Zeroes in on Houman Hemmati for CBER Lead
FDA narrows in on search for new biologics and vaccines leader - and we’re hearing @houmanhemmati is a top contender for CBER - https://t.co/qMx8wv32fG
Robust Bio Tools Demand Exhaustive Edge‑Case Testing
Hardest part of making bio tools is the endless testing of edge cases, to make sure that sequences are holy, circular permutation is accounted for, degenerate bases are considered, etc. To make robust code worthy of wetlab requires attention. I'm...
Ifinatamab Deruxtecan Granted Priority Review in the U.S. for Adult Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Who...
Daiichi Sankyo and Merck have received FDA acceptance and Priority Review for the Biologics License Application of ifinatamab deruxtecan, a first‑in‑class B7‑H3‑directed antibody‑drug conjugate, targeting adult patients with extensive‑stage small cell lung cancer (ES‑SCLC) who progressed after platinum chemotherapy. The...
Off‑the‑Shelf CAR‑T Shows Promise Delaying Lymphoma Relapse
Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma https://t.co/UrSNYpQFqB by @gwendolynawu $ALLO + 25%
Pancreatic Cancer Drug Nearly Doubles Survival in Trial
Revolution pancreatic cancer drug nearly doubles survival in key trial https://t.co/SvJicU0LIz @ByJonGardner $RVMD + 38%
Genetically Engineered Pets Are Coming
Genetic engineering, especially CRISPR, is moving beyond medicine and food into the pet market. U.S. regulators classify gene edits for pets as animal drugs, so companies must demonstrate safety for the animal and environment. Start‑up projects such as the Los...
Revolution Medicines' Pancreatic Cancer Drug Shows Late‑Stage Success
This is big. All cancers suck. Pancreatic somehow manages to suck even more. Revolution Medicines says its potential breakthrough pancreatic cancer drug succeeds in late-stage trial https://t.co/rFVsvi0mQD
Comprehensive Genomic Landscape of Small Bowel Adenocarcinoma Revealed
Genomic profiling of small bowel adenocarcinoma: a pooled analysis from 3 databases [May 14, 2024] Aparicio et al. @BrJCancer https://t.co/xfznlhD4fh #sbcsm #cagenome HT @OncoThor
The AI Value Gap and Why Validation Is a Practical First Win for Life Sciences
AI adoption in life‑sciences is hampered by a wide value gap, with only about 40% of firms seeing EBIT impact and most gains under 5%. A practical entry point is FDA‑oriented computer system validation (CSV) and computer software assurance, where...
Multiplexed In‑Vivo Screening Drives Next‑Gen Drug Development
Multiplexed in vivo screening is the future of drug development. @ManifoldBio is multiplexing protein therapies in vivo. @GordianBio is multiplexing gene therapies in vivo. @waypointbio is multiplexing cell therapies in vivo. GT Bio is multiplexing LNPs in vivo. 50Y portcos all https://t.co/DT2AwXbKtB
ALLO May
Has $ALLO found a niche for allo Car-T at last? It's early days, so the answer is maybe. Via @APEXONCO -> https://t.co/bO3A1hpAY8
IDEAYA/Servier PKC Drug Aces Uveal Melanoma Trial
IDEAYA’s PKC inhibitor darovasertib, combined with Pfizer’s crizotinib, achieved a statistically significant improvement in progression‑free survival in the phase 2/3 OptimUM‑02 trial for HLA‑A*02:01‑negative metastatic uveal melanoma. Median PFS extended to 6.9 months versus 3.1 months for investigator‑chosen immunotherapy, and the...